MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

Author:

Xu-Monette Zijun Y.1,Møller Michael B.2,Tzankov Alexander3,Montes-Moreno Santiago4,Hu Wenwei5,Manyam Ganiraju C.6,Kristensen Louise2,Fan Lei7,Visco Carlo8,Dybkær Karen9,Chiu April10,Tam Wayne11,Zu Youli12,Bhagat Govind13,Richards Kristy L.14,Hsi Eric D.15,Choi William W. L.16,van Krieken J. Han17,Huang Qin18,Huh Jooryung19,Ai Weiyun20,Ponzoni Maurilio21,Ferreri Andrés J. M.21,Wu Lin22,Zhao Xiaoying23,Bueso-Ramos Carlos E.1,Wang Sa A.1,Go Ronald S.24,Li Yong2526,Winter Jane N.27,Piris Miguel A.4,Medeiros L. Jeffrey1,Young Ken H.1

Affiliation:

1. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Odense University Hospital, Odense, Denmark;

3. University Hospital, Basel, Switzerland;

4. Hospital Universitario Marques de Valdecilla, Santander, Spain;

5. Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ;

6. Department of Biostatistics and Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX;

7. The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;

8. San Bortolo Hospital, Vicenza, Italy;

9. Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark;

10. Memorial Sloan-Kettering Cancer Center, New York, NY;

11. Weill Medical College of Cornell University, New York, NY;

12. The Methodist Hospital, Houston, TX;

13. Columbia University Medical Center and New York Presbyterian Hospital, New York, NY;

14. University of North Carolina School of Medicine, Chapel Hill, NC;

15. Cleveland Clinic, Cleveland, OH;

16. University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China;

17. Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands;

18. City of Hope National Medical Center, Duarte, CA;

19. Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea;

20. University of California San Francisco School of Medicine, San Francisco, CA;

21. San Raffaele H. Scientific Institute, Milan, Italy;

22. Roche Molecular Systems, Pleasanton, CA;

23. Zhejiang University School of Medicine, Second University Hospital, Hangzhou, China;

24. Mayo Clinic, Rochester, MN;

25. University of Louisville, Louisville, KY;

26. Shanghai Technology University, Shanghai, China; and

27. Feinberg School of Medicine, Northwestern University, Chicago, IL

Abstract

Key Points Phenotypic and genotypic profiling of MDM2 in DLBCL. MDM2 as a negative regulator of p53 tumor suppressor function.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3